- Home
- LNC vs GRFS Comparison
LNC vs GRFS Comparison
Compare LNC & GRFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LNC
- GRFS
- Stock Information
- Founded
- LNC 1905
- GRFS 1940
- Country
- LNC United States
- GRFS Spain
- Employees
- LNC N/A
- GRFS N/A
- Industry
- LNC Life Insurance
- GRFS Biotechnology: Pharmaceutical Preparations
- Sector
- LNC Finance
- GRFS Health Care
- Exchange
- LNC Nasdaq
- GRFS Nasdaq
- Market Cap
- LNC 8.0B
- GRFS 7.2B
- IPO Year
- LNC N/A
- GRFS 2006
- Fundamental
- Price
- LNC $42.89
- GRFS $9.97
- Analyst Decision
- LNC Hold
- GRFS Hold
- Analyst Count
- LNC 9
- GRFS 1
- Target Price
- LNC $39.56
- GRFS $10.30
- AVG Volume (30 Days)
- LNC 1.7M
- GRFS 925.1K
- Earning Date
- LNC 07-31-2025
- GRFS 01-01-0001
- Dividend Yield
- LNC 4.19%
- GRFS 1.45%
- EPS Growth
- LNC N/A
- GRFS 132.60
- EPS
- LNC 6.00
- GRFS 0.53
- Revenue
- LNC $18,036,000,000.00
- GRFS $8,744,226,659.00
- Revenue This Year
- LNC $7.16
- GRFS $6.00
- Revenue Next Year
- LNC $4.00
- GRFS $6.71
- P/E Ratio
- LNC $7.15
- GRFS $24.68
- Revenue Growth
- LNC 31.97
- GRFS 9.32
- 52 Week Low
- LNC $27.58
- GRFS $6.19
- 52 Week High
- LNC $43.12
- GRFS $11.14
- Technical
- Relative Strength Index (RSI)
- LNC 73.65
- GRFS 45.09
- Support Level
- LNC $41.70
- GRFS $9.79
- Resistance Level
- LNC $42.92
- GRFS $10.23
- Average True Range (ATR)
- LNC 0.76
- GRFS 0.21
- MACD
- LNC 0.10
- GRFS -0.11
- Stochastic Oscillator
- LNC 99.67
- GRFS 17.14
About LNC Lincoln National Corporation
Lincoln National Corp operates multiple insurance and retirement businesses. The company's operating segment includes Annuities; Retirement Plan Services; Life Insurance and Group Protection. Its products include fixed and indexed annuities, variable annuities, universal life insurance (UL), variable universal life insurance (VUL), linked-benefit UL and VUL, indexed universal life insurance (IUL), term life insurance, employer-sponsored retirement plans and services, and group life, disability and dental.
About GRFS Grifols S.A.
Grifols SA one of is global specialty plasma therapeutics companies developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend and enhance the lives of individuals who suffer from chronic and acute, often life-threatening, conditions, including primary and secondary immunological deficiencies, Chronic Inflammatory Demyelinating Polyneuropathy, immune-mediated ITP. Products and services are used to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases and a range of other medical conditions. Majority of revenue is from USA.